NDC 63323-113-01 - Pentam 300
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 63323-113
- Requested NDC
- 63323-113-01
- Package NDCs from labels
- 63323-113-01, 63323-113-10
- Manufacturer
- Fresenius Kabi USA, LLC
- Effective date
- 2022-09-13
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Pentam 300 - Fresenius Kabi USA, LLC | Fresenius Kabi USA, LLC | 2022-09-13 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 63323-113-01 | Pentam 300 | 3 mL in 1 VIAL | INJECTION, POWDER, LYOPHILIZED, | 3 | 3 | |
| 63323-113-10 | Pentam 300 | 10 in 1 TRAY | INJECTION, POWDER, LYOPHILIZED, | 10 | 3 |
DailyMed Dashboard NDC Coverage#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 63323-113-01 | EA - Each | 63323-113 | a8711af0-cae6-4608-b60b-5661909438de | 1 | 2024-04-05 |
| 63323-113-10 | EA - Each | 63323-113 | 7d710c79-d404-49fb-a1a9-1710eaffa1ff | 1 | 2012-07-24 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| PENTAMIDINE ISETHIONATE | ACTIVE INGREDIENT | V2P3K60DA2 | PENTAM 300 (PENTAMIDINE ISETHIONATE) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [APP PHARMACEUTICALS, LLC] | 1 | |
| PENTAMIDINE | ACTIVE MOIETY | 673LC5J4LQ | PENTAM 300 (PENTAMIDINE ISETHIONATE) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [APP PHARMACEUTICALS, LLC] | 1 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Pentamidine Isethionate | PENTAMIDINE ISETHIONATE | PAI Holdings, LLC dba PAI Pharma | 4c01d8e9-a25b-4046-8924-53bd9acd560d | 2026-06-12 | Warnings, Adverse reactions | V2P3K60DA2 |
| Pentamidine Isethionate | PENTAMIDINE ISETHIONATE | PAI Holdings, LLC dba PAI Pharma | d46aea4f-8f3f-4ce0-93d6-94e147f5a31a | 2026-05-07 | Warnings, Adverse reactions | 861601 V2P3K60DA2 |
| pentamidine isethionate | PENTAMIDINE ISETHIONATE | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | 5c14fbf2-e21f-44b3-b35c-06919d40d7e0 | 2025-10-31 | Warnings, Adverse reactions | 861601 V2P3K60DA2 |
| Pentamidine Isethionate | PENTAMIDINE ISETHIONATE | Seton Pharmaceuticals | c484f16e-9d97-4416-84a4-8ad8deaf5e19 | 2025-04-08 | Warnings, Adverse reactions | V2P3K60DA2 |
| Pentamidine Isethionate | PENTAMIDINE ISETHIONATE | Seton Pharmaceuticals | cb8e8155-5505-44d5-9dee-525e2e45b95d | 2025-04-02 | Warnings, Adverse reactions | 861601 V2P3K60DA2 |
| NebuPent | PENTAMIDINE ISETHIONATE | Fresenius Kabi USA, LLC | e2ad9d3c-b6c3-4f70-87e0-722a8ff94ccb | 2024-10-15 | Warnings, Adverse reactions | V2P3K60DA2 |
| Pentamidine Isethionate | PENTAMIDINE ISETHIONATE | XGen Pharmaceuticals DJB, Inc. | 490a231d-bb24-403d-9733-1a562ecd5917 | 2024-03-18 | Warnings, Adverse reactions | V2P3K60DA2 |
| PENTAMIDINE ISETHIONATE | PENTAMIDINE ISETHIONATE | XGen Pharmaceuticals DJB, Inc. | 860c799c-5199-4f0c-b21b-9910273474d9 | 2024-01-25 | Warnings, Adverse reactions | 861601 V2P3K60DA2 |
| Pentam 300 | PENTAMIDINE ISETHIONATE | Fresenius Kabi USA, LLC | cc2b635e-4840-4dc3-a177-5484371680e8 | 2022-09-13 | Warnings, Adverse reactions | NDA019264 63323-113-10 63323-113-01 63323-113 63323011301 861601 861604 5fe83fb0-2b64-40a2-a996-aaa6292e661e cc2b635e-4840-4dc3-a177-5484371680e8 V2P3K60DA2 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.